| Predicting HLA class II antigen presentation through integrated deep learning B Chen, MS Khodadoust, N Olsson, LE Wagar, E Fast, CL Liu, ... Nature biotechnology 37 (11), 1332-1343, 2019 | 268 | 2019 |
| Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity OAW Haabeth, TR Blake, CJ McKinlay, AA Tveita, A Sallets, ... Cancer research 79 (7), 1624-1634, 2019 | 103 | 2019 |
| Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints N Andor, EF Simonds, DK Czerwinski, J Chen, SM Grimes, ... Blood, The Journal of the American Society of Hematology 133 (10), 1119-1129, 2019 | 114 | 2019 |
| TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma SE Josefsson, K Beiske, YN Blaker, MS Førsund, H Holte, B Østenstad, ... Cancer immunology research 7 (3), 355-362, 2019 | 106 | 2019 |
| B-cell lymphomas present immunoglobulin neoantigens MS Khodadoust, N Olsson, B Chen, B Sworder, T Shree, CL Liu, L Zhang, ... Blood, The Journal of the American Society of Hematology 133 (8), 878-881, 2019 | 43 | 2019 |
| In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma MJ Frank, PM Reagan, NL Bartlett, LI Gordon, JW Friedberg, ... Cancer discovery 8 (10), 1258-1269, 2018 | 164 | 2018 |
| Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma DM Kurtz, F Scherer, MC Jin, J Soo, AFM Craig, MS Esfahani, JJ Chabon, ... Journal of Clinical Oncology 36 (28), 2845-2853, 2018 | 405 | 2018 |
| mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice OAW Haabeth, TR Blake, CJ McKinlay, RM Waymouth, PA Wender, ... Proceedings of the National Academy of Sciences 115 (39), E9153-E9161, 2018 | 115 | 2018 |
| Enhancing immunotherapy of STING agonist for lymphoma in preclinical models A Sallets, S Robinson, A Kardosh, R Levy Blood advances 2 (17), 2230-2241, 2018 | 42 | 2018 |
| Imaging activated T cells predicts response to cancer vaccines IS Alam, AT Mayer, I Sagiv-Barfi, K Wang, O Vermesh, DK Czerwinski, ... The Journal of clinical investigation 128 (6), 2569-2580, 2018 | 126 | 2018 |
| T‐cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins N Olsson, LM Schultz, L Zhang, MS Khodadoust, R Narayan, ... Proteomics 18 (12), 1700410, 2018 | 16 | 2018 |
| Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer NH Segal, AR He, T Doi, R Levy, S Bhatia, MJ Pishvaian, R Cesari, ... Clinical Cancer Research 24 (8), 1816-1823, 2018 | 239 | 2018 |
| Autologous iPSC-based vaccines elicit anti-tumor responses in vivo NG Kooreman, Y Kim, PE de Almeida, V Termglinchan, S Diecke, ... Cell stem cell 22 (4), 501-513. e7, 2018 | 166 | 2018 |
| T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling SE Josefsson, K Huse, A Kolstad, K Beiske, D Pende, CB Steen, ... Clinical Cancer Research 24 (4), 870-881, 2018 | 91 | 2018 |
| Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking AH Turaj, KL Cox, CA Penfold, RR French, CI Mockridge, JE Willoughby, ... Scientific reports 8 (1), 2278, 2018 | 40 | 2018 |
| Eradication of spontaneous malignancy by local immunotherapy I Sagiv-Barfi, DK Czerwinski, S Levy, IS Alam, AT Mayer, SS Gambhir, ... Science translational medicine 10 (426), eaan4488, 2018 | 377 | 2018 |
| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 5019 | 2017 |
| In-situ vaccination using sting agonists combined with immune-modulating antibodies to treat lymphoma A Sallets, A Kardosh, S Robinson, R Levy Blood 130, 4102, 2017 | 3 | 2017 |
| Methods for enhancing anti-tumor antibody therapy H Kohrt, R Houot, R Levy, AA Alizadeh, MJ Goldstein, J Torchia US Patent 9,758,589, 2017 | 24 | 2017 |
| Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody NH Segal, TF Logan, FS Hodi, D McDermott, I Melero, O Hamid, ... Clinical Cancer Research 23 (8), 1929-1936, 2017 | 387 | 2017 |
